Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTS: Chemoradiotherapy and TEM for Rectal Cancer
NCT01273051Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2010
- Primary completion
- Aug 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Radboud University Medical Center. Primary endpoint: Tumor Response. Started Nov 2010; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01273051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01273051.